{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:03:04Z","timestamp":1778504584221,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017667","name":"Chang Gung Memorial Hospital Center for Big Data Analytics and Statistics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017667","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG3M0882"],"award-info":[{"award-number":["CMRPG3M0882"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG3M2141"],"award-info":[{"award-number":["CMRPG3M2141"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"publisher","award":["CMRPG3M0881"],"award-info":[{"award-number":["CMRPG3M0881"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["109-2314-B-182 -049 -MY3"],"award-info":[{"award-number":["109-2314-B-182 -049 -MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-182-038"],"award-info":[{"award-number":["NSTC 112-2314-B-182-038"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.eprac.2024.11.016","type":"journal-article","created":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T22:42:25Z","timestamp":1734302545000},"page":"292-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Cardiovascular Outcomes Between Liraglutide and Dulaglutide Among Different Chronic Kidney Disease Stages in Patients With Type 2 Diabetes"],"prefix":"10.1016","volume":"31","author":[{"given":"Yu-Xuan","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Hsuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jui-Hung","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.eprac.2024.11.016_bib1","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.eprac.2024.11.016_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"10.1016\/j.eprac.2024.11.016_bib3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.eprac.2024.11.016_bib4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.016_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrneph.2015.173","article-title":"Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease","volume":"12","author":"Thomas","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.1016\/j.eprac.2024.11.016_bib6","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.016_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"10193","key":"10.1016\/j.eprac.2024.11.016_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10193","key":"10.1016\/j.eprac.2024.11.016_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.eprac.2024.11.016_bib10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2024.11.016_bib11","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/dc11-0442","article-title":"Globalization of diabetes: the role of diet, lifestyle, and genes","volume":"34","author":"Hu","year":"2011","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2024.11.016_bib12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.016_bib13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2337\/dc14-2883","article-title":"Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial","volume":"39","author":"Davies","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2024.11.016_bib14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/dom.14244","article-title":"Patients' preferences for once-daily oral versus once-weekly injectable diabetes medications: the REVISE study","volume":"23","author":"Boye","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2024.11.016_bib15","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1210\/jc.2009-1966","article-title":"Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know","volume":"95","author":"Smith","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24008668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T18:50:14Z","timestamp":1741027814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24008668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1530891X24008668"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.11.016","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Cardiovascular Outcomes Between Liraglutide and Dulaglutide Among Different Chronic Kidney Disease Stages in Patients With Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}